Evolving paradigms in multifocal breast cancer

Seminars in Cancer Biology

Volumn 31, Issue , 2015, Pages 111-118

  Salgado, Roberto ^a,b   Aftimos, Philippe ^b   Sotiriou, Christos ^b   Desmedt, Christine ^b  

^a Department of Anesthesiology and Pain Management   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer subtyping; Clinical trials; Inter lesion heterogeneity; Multifocal breast cancer

Indexed keywords

AFATINIB; EVEROLIMUS; LAPATINIB; NERATINIB; PERTUZUMAB; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; GENETIC HETEROGENEITY; HUMAN; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; MULTIFOCAL BREAST CANCER; PREVALENCE; REVIEW; BREAST; BREAST NEOPLASMS; CLASSIFICATION; FEMALE; METABOLISM; METASTASIS; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84923222434     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.07.002     Document Type: Review

References (63)

1. Bendifallah S., Werkoff F.G., Borie-Moutafoff C., Antoine M., Chopier J., Gligorov J., et al. Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications. Surg Oncol 2010, 19(4):e115-e123.
2. Lynch S.P., Lei X., Chavez-MacGregor M., Hsu L., Meric-Bernstam F., Buchholz T.A., et al. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 2012, 23(12):3063-9.4.
3. Wolters R., Wöckel A., Janni W., Novopashenny I., Ebner F., Kreienberg R. Comparing the outcome between multicentric and multifocal breast cancer: what's the impact on survival, and is there a role for guideline-adherent therapy? A retrospective cohort study of 8935 patients. Breast Cancer Res Treat 2013, 142(3):579-590.
4. Chua B., Ung O., Taylor R., Boyages J. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg 2001, 71(12):723-728.
5. Chung A.P., Huynh K., Kidner T., Mirzadehgan P., Sim M.S., Guiliano A.E. Comparison of outcomes of breast conserving therapy in multifocal and unifocal invasive breast cancer. J Am Coll Surg 2012, 215(1):137-146.
6. Fisher E.R., Gregorio R., Redmond C. Pathological findings from the National Surgical Adjuvant Breast Project (Protocol n 4). Observations concerning the multicentricity of mammary breast cancer. Cancer 1975, 35(1):247-254.
7. Jesinger R.A. Breast anatomy for the interventionalist. Tech Vasc Interv Radiol 2014, 17(1):3-9.
8. Khan S. The many questions that surround multicentric and multifocal breast cancer. Breast J 2010, 16(3):219-221.
9. American Joint Committee on Cancer: Breast AJCC cancer staging manual 2010, 347-376. Springer, New York, NY. 7th ed. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
10. Senkus E., Kyriakides S., Penault-Llorca F., Poortmans P., Thompson A., Zackrisson S., et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(Suppl. 6):vi7-vi23.
11. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24(9):2206-2223.
12. Moon H.G., Han W., Kim J.Y., Kim S.J., Yoon J.H., Oh S.J., et al. Effect of multiple invasive foci on breast cancer outcomes according to the molecular subtypes: a report from the Korean Breast Cancer Society. Ann Oncol 2013, 24:2298-2304.
13. Garimella V., Long E.D., O'Kane S.L., Drew P.J., Cawkwell L. Oestrogen and progesterone receptor status of individual foci in multifocal invasive ductal breast cancer. Acta Oncol 2007, 46:204-207.
14. Bethune G.C., Brendan Mullen J., Chang M.C. HER2 testing of multifocal invasive breast cancer. How many blocks are enough?. Am J Clin Pathol 2013, 140:588-592.
15. Choi Y., Kim E.J., Seol H.S., Lee H.E., Jang M.J., Kim S.M. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast. Hum Pathol 2012, 43:48-55.
16. Middleton L.P., Vlastos G., Mirza N.Q., Eva S., Sahin A.A. Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer 2002, 94(7):1910-1916.
17. Buggi F., Folli S., Curcio A., Casadei-Giunchi D., Rocca A., Pietri E., et al. Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all lesions justified?. Ann Oncol 2012, 23:2042-2046.
18. Pekar G., Gere M., Tarjan M., Hellberg D., Tot T. Molecular phenotype of the foci in multifocal invasive breast carcinomas: intertumoral heterogeneity is related to shorter survival and may influence the choice of therapy. Cancer 2014, 120(1):26-34.
19. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol 2010, 28(16):2784-2795.
20. Salgado R, Maetens M, Fumagalli D, et al. Improving Translational Research Sample Collection in International Trials. Breast International Group, http://www.bigagainstbreastcancer.org/.
21. Weissenbacher T.M., Zschage M., Janni W., Jeschke U., Dimpfl T., Mayr D., et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?. Breast Cancer Res Treat 2010, 122(July (1)):27-34.
22. Katz A., Strom E.A., Buchholz T.A., Theriault R., Singletary S.E., McNeese M.D. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 2001, 50(July (3)):735-742.
23. Lynch S.P., Lei X., Hsu L., Meric-Bernstam F., Buchholz T.A., Zhang H., et al. Breast cancer multifocality and multicentricity and locoregional recurrence. Oncologist 2013, 18(11):1167-1173.
24. Yerushalmi R., Tyldesley S., Woods R., Kennecke H.F., Speers C., Gelmon K.A. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?. Ann Oncol 2012, 23(April (4)):876-881.
25. Vlastos G1, Rubio I.T., Mirza N.Q., Newman L.A., Aurora R., Alderfer J., et al. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1-M0 breast cancer. Ann Surg Oncol 2000, 7(8):581-587.
26. Hilton J.F., Bouganim N., Dong B., Chapman J.W., Arnaout A., O'Malley F., et al. Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials. Breast Cancer Res Treat 2013, 142(November (1)):143-151.
27. Rezo A., Dahlstrom J., Shadbolt B., Rodins K., Zhang Y., Davis A.J. ACT & SENSW BCTG. Tumor size and survival in multicentric and multifocal breast cancer. Breast 2011, 20(June (3)):259-263.
28. Cabioglu N., Ozmen V., Kaya H., Tuzlali S., Igci A., Muslumanoglu M., et al. Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg 2009, 208(1):67-74.
29. Andea A.A., Wallis T., Newman L.A., Bouwman D., Dey J., Visscher D.W. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer 2002, 94(March (5)):1383-1390.
30. Boyages J., Jayasinghe U.W., Coombs N. Multifocal breast cancer and survival: each focus does matter particularly for larger tumours. Eur J Cancer 2010, 46(11):1990-1996.
31. Coombs N.J., Boyages J. Multifocal and multicentric breast cancer: does each focus matter?. J Clin Oncol 2005, 23(October (30)):7497-7502.
32. Donker M., Straver M.E., van Tienhoven G., van de Velde C.J., Mansel R.E., Litière S., et al. Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: identification rate and nodal outcome. Eur J Cancer 2013, 49(9):2093-2100.
33. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2005, 365(9472):1687-1717.
34. National Institutes of Health Consensus Development Conference Statement: Adjuvant Chemotherapy for Breast Cancer, September 9-11, 1985. CA Cancer J Clin 1986, 36(1):42-47.
35. National Cancer Institute: clinical alert from the National Cancer Institute. Breast Cancer Res Treat 1988, 12:3-5.
36. NIH Consensus Conference: treatment of early-stage breast cancer. J Am Med Assoc 1991, 265:391-395.
37. Schootman M., Jeffe D., Reschke A., Aft R. The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States. Breast Cancer Res Treat 2000, 85(3):219-222.
38. Toole M.J., Kidwell K.M., Van Poznak C. Oncotype dx results in multiple primary breast cancers. Breast Cancer (Auckl) 2014, 9(8):1-6.
39. Dawson P.J., Baekey P.A., Clark R.A. Mechanisms of multifocal breast cancer: an immunocytochemical study. Hum Pathol 1995, 26(9):965-969.
40. Noguchi S., Aihara T., Koyama H., Motomura K., Inaji H., Imaoka S. Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer 1994, 74:872-877.
41. Ghazani A.A., Arneson N., Warren K., Pintilie M., Bayani J., Squire J.A. Genomic alterations in sporadic synchronous primary breast cancer using array and metaphase comparative genomic hybridization. Neoplasia 2007, 9(6):511-520.
42. Teixeira M.R., Pandis N., Bardi G., Andersen J.A., Bohler P.J., Qvist H., et al. Discrimination between multicentric and multifocal breast carcinoma by cytogenetic investigation of macroscopically distinct ipsilateral lesions. Genes Chromosomes Cancer 1997, 18(3):170-174.
43. Teixeira M.R., Pandis N., Bardi G., Andersen J.A., Mandahl N., Mitelman F., et al. Cytogenetic analysis of multifocal breast carcinomas: detection of karyotypically unrelated clones as well as clonal similarities between tumour foci. Br J Cancer 1994, 70:922-927.
44. Weissenbacher T., Hirte E., Kuhn C., Janni W., Mayr D., Karsten U., et al. Multicentric and multifocal versus unifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology. BMC Cancer 2013, 13:361.
45. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
46. Moon H.G., Han W., Kim J.Y., Kim S.J., Yoon J.H., Oh S.J., et al. Effect of multiple invasive foci on breast cancer outcomes according to the molecular subtypes: a report from the Korean Breast Cancer Society. Ann Oncol 2013, 24(9):2298-2304.
47. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I. Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353(16):1659-1672.
48. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
49. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. Breast Cancer International Research Group Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365(14):1273-1283.
50. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366(6):520-529.
51. Amir E., Miller N., Geddie W., Freedman O., Kassam F., Simmons C., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012, 30(6):587-592.
52. Niikura N., Liu J., Hayashi N., Mittendorf E.A., Gong Y., Palla S.L., et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012, 30(6):593-599.
53. Amir E., Clemons M., Purdie C.A., Miller N., Quinlan P., Geddie W., et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012, 38(6):708-714.
54. Dawson S.J., Tsui D.W., Murtaza M., Biggs H., Rueda O.M., Chin S.F., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013, 368(13):1199-1209.
55. Ustaalioglu B.O., Bilici A., Kefeli U., Şeker M., Oncel M., Gezen C., et al. The importance of multifocal/multicentric tumor on the disease-free survival of breast cancer patients: single center experience. Am J Clin Oncol 2012, 35(December (6)):580-586.
56. Pekar G., Hofmeyer S., Tabár L., Tarján M., Chen T.H., Yen A.M., et al. Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes. Cancer 2013, 119(6):1132-1139.
57. Tot T., Gere M., Pekár G., Tarján M., Hofmeyer S., Hellberg D., et al. Breast cancer multifocality, disease extent, and survival. Hum Pathol 2011, 42(11):1761-1769.
58. Tot T., Pekár G. Multifocality in "basal-like" breast carcinomas and its influence on lymph node status. Ann Surg Oncol 2011, 18(6):1671-1677.
59. Yerushalmi R., Kennecke H., Woods R., Olivotto I.A., Speers C., Gelmon K.A. Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 2009, 117(2):365-370.
60. Pedersen L., Gunnarsdottir K.A., Rasmussen B.B., Moeller S., Lanng C. The prognostic influence of multifocality in breast cancer patients. Breast 2004, 13(3):188-193.
61. Joergensen L.E., Gunnarsdottir K.A., Lanng C., Moeller S., Rasmussen B.B. Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996-2001. Breast 2008, 17(6):587-591.
62. Katz A., Strom E.A., Buchholz T.A., Theriault R., Singletary S.E., McNeese M.D. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 2001, 50(3):735-742.
63. Litton J.K., Eralp Y., Gonzalez-Angulo A.M., Broglio K., Uyei A., Hortobagyi G.N., et al. Multifocal breast cancer in women < or =35 years old. Cancer 2007, 110(7):1445-1450.